Charles River Laboratories | CRL - Le Bénéfice D'Exploitation





Le Bénéfice D'Exploitation Changement Date
Agilent USD 444M 45M 2026-06
Align Technology USD 191.32M 13.27M 2026-06
Bio-Rad Laboratories USD 72.6M 38.5M 2026-06
Bruker USD 69.6M 59.4M 2026-06
Cardinal Health USD 814M 47M 2026-06
Charles River Laboratories USD 119.89M 9K 2026-06
Cigna USD 2.76B 204M 2026-03
Concord Medical Services Hldg CNY -94.68M 49.97M 2025-12
CVS Health USD 6.73B 2.05B 2026-06
Danaher USD 1.13B 217M 2026-06
Dentsply International USD 84M 52M 2026-06
Elevance Health USD 2.3B 8.11B 2026-06
Humana USD 1.36B 394M 2026-06
Illumina USD 260M 21M 2026-06
Incyte USD 700.4M 376.22M 2026-06
Intrexon USD -60.84M 26.62M 2024-06
IQVIA Holdings USD 2.6B 2.03B 2026-06
Laboratory Of America USD 456.7M 46.6M 2026-06
Lakefront Biotherapeutics EUR -43.51M 20.19M 2026-06
Lonza CHF 673M 243M 2025-06
McKesson USD 1.42B 415M 2026-06
Merck EUR 1.1B 51M 2026-06
Mettler Toledo International USD 287.55M 53.61M 2026-06
Novartis USD 4.75B 515M 2026-06
Pfizer USD 667M 4.32B 2026-06
Quest Diagnostics USD 459M 60M 2026-06
Revvity USD 126.14M 43.36M 2026-06
Thermo Fisher Scientific USD 2.18B 273M 2026-06
United Therapeutics USD 330.8M 5M 2026-06
UnitedHealth USD 7.99B 1.05B 2026-06
Veradigm USD -45.47M 70.47M 2022-12
Waters USD -86M 234M 2026-06
West Pharmaceutical Services USD 179.1M 2M 2026-06